PD-L1 in immune-escape of breast and prostate cancers: from biology to therapy.

about

PD-L1 in immune-escape of breast and prostate cancers: from biology to therapy.

Item

http://www.wikidata.org/entity/Q47912397

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

PD-L1 in immune-escape of breast and prostate cancers: from biology to therapy.

@en

PD-L1 in immune-escape of breast and prostate cancers: from biology to therapy.

@nl

type

Item

label

PD-L1 in immune-escape of breast and prostate cancers: from biology to therapy.

@en

PD-L1 in immune-escape of breast and prostate cancers: from biology to therapy.

@nl

prefLabel

PD-L1 in immune-escape of breast and prostate cancers: from biology to therapy.

@en

PD-L1 in immune-escape of breast and prostate cancers: from biology to therapy.

@nl

P1476

PD-L1 in immune-escape of breast and prostate cancers: from biology to therapy.

@en

P2093

Alessandro Mauriello

http://www.w3.org/2001/XMLSchema#string

Chiara Cerroni

http://www.w3.org/2001/XMLSchema#string

Daniela Nardozi

http://www.w3.org/2001/XMLSchema#string

Elena Bonanno

http://www.w3.org/2001/XMLSchema#string

Manuel Scimeca

http://www.w3.org/2001/XMLSchema#string

Rita Bonfiglio

http://www.w3.org/2001/XMLSchema#string

P2860

The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment

The three Es of cancer immunoediting

Recent changes in prostate cancer screening practices and prostate cancer epidemiology.

Novel targeted therapeutics for metastatic castration-resistant prostate cancer.

T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics.

The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors.

Pathogen recognition by the long pentraxin PTX3.

miR-34a Silences c-SRC to Attenuate Tumor Growth in Triple-Negative Breast Cancer.

The B7 family and cancer therapy: costimulation and coinhibition.

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.

P304

2129-2131

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.2217/FON-2017-0278

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28984478

http://www.w3.org/2001/XMLSchema#string